LONDON, April 16,
2024 /PRNewswire/ -- Virax Biolabs Group Limited
(NASDAQ: VRAX) ("Virax" or the "Company"), an innovative
biotechnology company focused on the detection of immune responses
and diagnosis of viral diseases, announced today that it will be
hosting a booth at the European Society of Clinical Microbiology
and Infectious Diseases Global 2024 (ESCMID) on April 27-30, 2024, in Barcelona, Spain.
The Company will be showcasing its portfolio of products for
research use at Booth F43, and management will be available for
discussions with research organizations and potential
customers.
The ESCMID Global 2024 (formally ECCMID), is a leading global
forum for infectious diseases, bringing together international
experts in related fields to present their latest findings to an
audience of over 20,000 colleagues and industry leaders. The
congress also features a hybrid format, to facilitate an onsite and
online experience for attendees allowing for remote and
face-to-face opportunities.
About Virax Biolabs Group Limited.
Virax Biolabs Group Limited is an innovative biotechnology
company focused on the detection of immune responses to and
diagnosis of viral diseases. Virax Biolabs Group Limited is
currently developing T-Cell-based test technologies with the
intention of providing an immunology profiling platform.
T-Cell testing can be particularly effective in the diagnosis
and therapeutics of post-viral syndromes such as Long COVID and
other chronic conditions linked to immune dysregulation.
For more information, please
visit www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This press release contains forward-looking statements. In
addition, from time to time, we or our representatives may make
forward-looking statements orally or in writing. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. These forward-looking
statements are based on information currently available to Virax
and its current plans or expectations and are subject to a number
of known and unknown uncertainties, risks and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. These and other important factors are
described in detail in the "Risk Factors" section of Virax's Annual
Report on Form 20-F for the year ended March
31, 2023. Although we believe the expectations reflected in
such forward-looking statements are reasonable, we can give no
assurance that such expectations will prove to be correct. We are
not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
Investor Relations Contact:
Russo Partners,
LLC
Nic Johnson and Adanna
Alexander
12 West 27th Street
4th Floor
New York, NY 10001
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-to-participate-at-escmid-global-2024-302118026.html
SOURCE Virax Biolabs